Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors.
Mridula KrishnanPooja KasinathRobin HighFang YuBenjamin A TeplyPublished in: JCO oncology practice (2021)
Despite the appeal of ICI in patients with advanced malignancy and poor PS, outcomes in this cohort were poor. Prospective trials defining the activity and role of ICI in poor PS are urgently needed.